Home › Funds › Decheng Capital LLC › CGON
Decheng Capital LLC position in CGON
CG ONCOLOGY INC · Health Care
Decheng Capital LLC reported holding 6,371,669 shares of CGON (CG ONCOLOGY INC) in its Q3 2026 13F filing — a position valued at US$451.7M, representing 65.93% of its reported portfolio and ranking #1 among its reported holdings. Decheng Capital LLC has disclosed CGON holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Decheng Capital LLC's CGON position evolved
Decheng Capital LLC first disclosed a stake in CGON in Q1 2024 at 5,458,810 shares (US$239.6M). The position peaked in Q2 2026 at 6,371,669 shares, worth US$452.7M. Across 11 filings, Decheng Capital LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 6,371,669 shares valued at US$451.7M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 5.46M | $239.64M | New |
| Q2 2024 | 5.46M | $172.33M | Hold |
| Q3 2024 | 5.48M | $206.72M | Hold |
| Q4 2024 | 6.37M | $182.74M | Add |
| Q1 2025 | 6.37M | $156.04M | Hold |
| Q2 2025 | 6.37M | $165.66M | Hold |
| Q3 2025 | 6.37M | $256.65M | Hold |
| Q4 2025 | 6.37M | $264.55M | Hold |
| Q1 2026 | 6.37M | $431.23M | Hold |
| Q2 2026 | 6.37M | $452.71M | Hold |
| Q3 2026 | 6.37M | $451.69M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CGON and 13F data
CGON (CG ONCOLOGY INC) is a Health Care company. 50 other funds we track also report a position in CGON — the largest reported positions include RTW INVESTMENTS, LP (US$605.0M), TCG Crossover Management, LLC (US$260.8M), Foresite Capital Management VI LLC (US$168.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CGON
- RTW INVESTMENTS, LP 8.51M sh · $604.96M · Q2 2026
- TCG Crossover Management, LLC 3.67M sh · $260.77M · Q2 2026
- Foresite Capital Management VI LLC 2.37M sh · $168.36M · Q2 2026
- Seven Fleet Capital Management LP 1.89M sh · $134.02M · Q2 2026
- DV Trading LLC 1.44M sh · $102.27M · Q2 2026
- Avidity Partners Management LP 1.40M sh · $99.40M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 1.13M sh · $80.39M · Q2 2026
- Foresite Capital Management V, LLC 1.08M sh · $76.67M · Q2 2026
- Logos Global Management LP 1.00M sh · $71.05M · Q2 2026
- ORBIMED ADVISORS LLC 972.80K sh · $69.12M · Q2 2026
- Jefferies Financial Group Inc. 835.34K sh · $59.22M · Q3 2026
- EcoR1 Capital, LLC 561.50K sh · $39.89M · Q2 2026
More on Decheng Capital LLC
FAQ
How long has Decheng Capital LLC held CGON?
Decheng Capital LLC has disclosed CGON holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is Decheng Capital LLC's current position in CGON?
As of Q3 2026, Decheng Capital LLC holds 6.37M shares of CGON (CG ONCOLOGY INC), valued at $451.69M, representing 65.93% of its reported portfolio and ranking #1.
Has Decheng Capital LLC been buying or selling CGON?
In the latest 13F filing (Q3 2026), Decheng Capital LLC held unchanged its position in CGON. The position peaked in Q2 2026 at 6.37M shares.
Which other funds hold CGON?
Other major institutional holders of CGON include RTW INVESTMENTS, LP, TCG Crossover Management, LLC, Foresite Capital Management VI LLC, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.